<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><title>Email Template - Geometric</title><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:Georgia;
panose-1:2 4 5 2 5 4 5 2 3 3;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
line-height:normal;
font-size:12.0pt;
font-family:"Times New Roman","serif";
color:windowtext;}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
margin:0cm;
margin-bottom:.0001pt;
line-height:normal;
font-size:45.0pt;
font-family:"Helvetica","sans-serif";
color:#333333;
font-weight:normal;}
h2
{mso-style-priority:9;
mso-style-link:"Heading 2 Char";
margin:0cm;
margin-bottom:.0001pt;
line-height:normal;
font-size:27.0pt;
font-family:"Helvetica","sans-serif";
color:#333333;
font-weight:bold;}
h3
{mso-style-priority:9;
mso-style-link:"Heading 3 Char";
margin:0cm;
margin-bottom:.0001pt;
line-height:normal;
font-size:18.0pt;
font-family:"Helvetica","sans-serif";
color:#333333;
font-weight:bold;}
h4
{mso-style-priority:9;
mso-style-link:"Heading 4 Char";
margin-top:9.0pt;
margin-right:0cm;
margin-bottom:9.0pt;
margin-left:0cm;
line-height:normal;
font-size:13.5pt;
font-family:"Helvetica","sans-serif";
color:#333333;
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#4B98D7;
text-decoration:none none;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#4B98D7;
text-decoration:none none;}
p
{mso-style-priority:99;
margin:0cm;
margin-bottom:.0001pt;
line-height:18.0pt;
font-size:13.0pt;
font-family:"Georgia","serif";
color:#333333;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Cambria","serif";
color:#365F91;
font-weight:bold;}
span.Heading2Char
{mso-style-name:"Heading 2 Char";
mso-style-priority:9;
mso-style-link:"Heading 2";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;}
span.Heading3Char
{mso-style-name:"Heading 3 Char";
mso-style-priority:9;
mso-style-link:"Heading 3";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;}
span.Heading4Char
{mso-style-name:"Heading 4 Char";
mso-style-priority:9;
mso-style-link:"Heading 4";
font-family:"Cambria","serif";
color:#4F81BD;
font-weight:bold;
font-style:italic;}
span.EmailStyle22
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body bgcolor=white lang=EN-CA link="#4B98D7" vlink="#4B98D7"><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See survey below.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Glen Tolhurst<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Chair- PCCN W-W <o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Jackie Manthorne [mailto:jmanthorne=survivornet.ca@createsend1.com] <b>On Behalf Of </b>Jackie Manthorne<br><br><o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;background:white'><tr><td style='padding:0cm 0cm 0cm 0cm'><div align=center><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td valign=top style='padding:0cm 0cm 0cm 0cm'><p class=MsoNormal><img width=624 height=12 id="_x0000_i1025" src="http://i5.createsend1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/spacer-top.jpg"><o:p></o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td width=221 style='width:165.75pt;padding:0cm 0cm 0cm 0cm'><p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Is this email not displaying correctly?<o:p></o:p></span></p></td><td width=285 valign=top style='width:213.75pt;padding:0cm 0cm 0cm 0cm'><p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'><a href="http://ccsn.createsend1.com/t/r-e-oqktjy-jjikahia-r/" id=vw><b><span style='color:#333333;background:#E9E8E8'>View it in a web browser</span></b></a> <o:p></o:p></span></p></td><td width=118 valign=top style='width:88.5pt;padding:0cm 0cm 0cm 0cm'><p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'><a href="http://ccsn.forwardtomyfriend.com/r-jjikahia-8B18637E-oqktjy-l-y" id=ff><b><span style='color:white;background:#989480'>Forward to a friend</span></b></a> <o:p></o:p></span></p></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td width=624 valign=top style='width:468.0pt;padding:0cm 0cm 0cm 0cm'><p><img border=0 width=624 height=10 id="_x0000_i1026" src="http://i7.createsend1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/line-break.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt' id=email-content><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr style='height:15.0pt'><td valign=top style='padding:0cm 0cm 0cm 0cm;height:15.0pt'><p class=MsoNormal><img border=0 width=622 height=313 id="_x0000_i1027" src="http://i6.createsend1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/img1.jpg"><o:p></o:p></p></td></tr></table><h2>CCSN March 18, 2013 E-alert<o:p></o:p></h2><p>The Canadian Cancer Survivor Network (CCSN) is a national network of patients, families, survivors, friends, community partners, funders and sponsors who have come together to take action to promote the very best standards of care, whether it be early diagnosis, timely treatment and follow-up care, support for cancer patients, or issues related to survivorship or quality of end of life care.<o:p></o:p></p></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr style='height:22.5pt'><td width=624 style='width:468.0pt;padding:0cm 0cm 0cm 0cm;height:22.5pt'><p class=MsoNormal><img border=0 width=624 height=13 id="_x0000_i1028" src="http://i8.createsend1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/line-break-2.jpg"><o:p></o:p></p></td></tr></table><p class=MsoNormal><o:p> </o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td width=624 valign=top style='width:468.0pt;padding:0cm 0cm 0cm 0cm'><h3>NEW! Canadian Cancer Survivor Network Survey on Zytiga<o:p></o:p></h3><p> <o:p></o:p></p><p>CCSN would like to thank you for filling out our recent survey on Xtandi, which helped us prepare our patient group submission to the pan-Canadian Oncology Drug Review. Thanks to your willingness to complete this survey, we had 30 completed surveys when the survey closed!<o:p></o:p></p><p> <o:p></o:p></p><p>We are pleased to let you know that A SECOND SURVEY is now open for Zytiga (abiraterone acetate), another new medication for metastatic castration-resistant prostate cancer.<o:p></o:p></p><p> <o:p></o:p></p><p>This medication has been available in Canada since 2011 for patients with metastatic castration-resistant prostate cancer in the post-chemotherapy stages. This national cancer drug review will consider its use in the pre-chemotherapy stage. The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.<o:p></o:p></p><p> <o:p></o:p></p><p>The survey is available NOW and will remain open until April 5, 2013.<o:p></o:p></p><p><br>To access the survey, please go to <a href="https://www.surveymonkey.com/s/LN7K2BY">https://www.surveymonkey.com/s/LN7K2BY</a><o:p></o:p></p></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr style='height:30.0pt'><td style='padding:0cm 0cm 0cm 0cm;height:30.0pt'><p class=MsoNormal><img border=0 width=624 height=10 id="_x0000_i1029" src="http://i7.createsend1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/line-break.jpg"><o:p></o:p></p></td></tr></table></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr style='height:22.5pt'><td width=624 style='width:468.0pt;padding:0cm 0cm 0cm 0cm;height:22.5pt'><p class=MsoNormal><img border=0 width=624 height=13 id="_x0000_i1030" src="http://i8.createsend1.com/ti/r/05/11E/5D2/035741/images/geometric/geometric/html/images/line-break-2.jpg"><o:p></o:p></p></td></tr></table><p class=MsoNormal><span style='display:none'><o:p> </o:p></span></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624 style='width:468.0pt'><tr><td style='padding:0cm 0cm 0cm 0cm'><p>You are receiving this newsletter because you subscribed to our Newsletter.<o:p></o:p></p><p><a href="http://ccsn.createsend1.com/t/r-u-oqktjy-jjikahia-j/">Unsubscribe instantly.</a><o:p></o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%'><tr style='height:22.5pt'><td style='padding:0cm 0cm 0cm 0cm;height:22.5pt'></td></tr></table></td></tr></table></td></tr></table></td></tr></table></div></td></tr></table><p class=MsoNormal><img border=0 width=1 height=1 id="_x0000_i1031" src="https://createsend1.com/t/r-o-oqktjy-jjikahia/o.gif"><o:p></o:p></p></div></body></html>